Crohn¿ disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease Articles uri icon

authors

  • Martinez Dominguez, Samuel J.
  • Garcia Mateo, Sandra
  • Gargallo Puyuelo, Carla J.
  • Gallego Llera, Beatriz
  • Refaie, Engy
  • Callau, Pilar
  • Mendi, Carolina
  • ALMEIDA DE MATOS BAPTISTA, PEDRO MIGUEL
  • Hernandez Ainsa, Maria
  • Arroyo Villarino, Maria Teresa
  • Lopez de la Cruz, Julia
  • Martinez Garcia, Javier
  • Alfambra, Erika
  • Simon Marco, Miguel Angel
  • Ampuero, Javier
  • Gomollon, Fernando

publication date

  • February 2024

volume

  • 120

International Standard Serial Number (ISSN)

  • 0953-6205

Electronic International Standard Serial Number (EISSN)

  • 1879-0828

abstract

  • Background and aims: Controversial data have been reported regarding the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Inflammatory Bowel Disease (IBD) population and IBD-related risk factors. The aim of the study was to assess the prevalence and risk factors associated with NAFLD and liver fibrosis in IBD participants compared with non-IBD controls. Methods: Cross-sectional, case-control study including 741 IBD cases and 170 non-IBD controls, matched by sex and age. All participants underwent liver ultrasound, transient elastography and laboratory tests. A logistic regression multivariable analysis was performed adjusting for classic metabolic risk factors and history of systemic steroid use. Results: The prevalence of NAFLD and significant liver fibrosis was 45 % and 10 % in IBD group, and 40 % and 2.9 % in non-IBD group (p = 0.255 and 0.062, respectively). Longer IBD duration (aOR 1.02 95% CI (1.001¿04)) and older age at IBD diagnosis (aOR 1.02 95 % CI (1.001¿04)) were independent risk factors for NAFLD in IBD group. Crohn¿ Disease was an independent risk factor for significant liver fibrosis in participants with IBD and NAFLD (aOR 3.97 95 % CI (1.78¿96)). NAFLD occurred at lower BMI levels in IBD group with NAFLD compared to non-IBD group with NAFLD (aOR 0.92 95 % CI (0.87¿98)). Conclusions: Although we found no differences in the prevalence of NAFLD and liver fibrosis between IBD group and non-IBD group, our findings suggest that liver fibrosis progression should be closely monitored in patients with concomitant CD and NAFLD, more in particular in those with long standing active disease.

keywords

  • inflammatory bowel disease; liver fibrosis; nafld